March 10, 2025 16:30 ET | Source: SEALSQ Geneva, Switzerland, March 10, 2025 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES)…
– Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure,…
Data presented in an oral session at the Society for Immunotherapy of Cancer 39th Annual Meeting, where it was selected…